Clinical Trial Update: Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of cediranib and olaparib for recurrent ovarian cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Cediranib (Cediranib)
• Olaparib (Olaparib)

Snippet

Sponsor: Mario Negri Institute for Pharmacological Research | Conditions: Ovarian Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2025-01-10